Get the Stockscreener App
105.46
1.61%
-1.73
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $105.46, with a volume of 81.59M.
It is down -1.61% in the last 24 hours and down -6.02% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$107.19
Open:
$107.04
24h Volume:
81.59M
Relative Volume:
7.72
Market Cap:
$183.26B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
28.37
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-2.38%
1M Performance:
-6.02%
6M Performance:
-22.48%
1Y Performance:
-16.82%
1-Day Range:
$105.40
$107.79
1-Week Range:
$105.40
$111.86
52-Week Range:
$105.27
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
105.46 | 183.26B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
335.67 | 128.46B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.16 | 110.62B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.48 | 103.10B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.50 | 47.92B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
St. Louis Financial Planners Asset Management LLC Purchases New Position in Abbott Laboratories $ABT - MarketBeat
Abbott Labs’ $23 billion deal to acquire Madison’s Exact Sciences set to close Monday - Wisconsin State Journal
Abbott Laboratories $ABT Shares Purchased by Covea Finance - MarketBeat
Abbott Laboratories Finalizes Major Acquisition in Cancer Diagnostics - AD HOC NEWS
Is Abbott Laboratories (ABT) Share Price Weakness Creating A Long Term Opportunity? - simplywall.st
Abbott Laboratories to close on Exact Sciences purchase - Channel 3000
Abbott (NYSE:ABT) Expands Diagnostics With Exact Sciences Amid S&P 500 Futures - Kalkine Media
Exact Sciences and Abbott receive all approvals for planned merger By Investing.com - Investing.com India
Abbott Laboratories’ CGM Growth Story Looks Obvious—But the NEXT Leg Is Even Bigger! - Smartkarma
Abbott Laboratories to close $21B Exact Sciences deal Monday - Modern Healthcare
When Abbott Labs expects to close on $23B takeover of Exact Sciences - The Business Journals
Abbott expects to close on acquisition of Madison’s Exact Sciences on Monday - WPR
Abbott closing Exact Sciences acquisition next week - Channel 3000
Abbott, Boston Scientific Oppose Spinal Cord Stimulator Lawsuit MDL - AboutLawsuits.com
Exact Sciences Corp Announces Merger Agreement with Abbott Laboratories – SEC 8-K Filing March 2026 - Minichart
Abbott to close $21B Exact Sciences acquisition Monday - MedTech Dive
Abbott (ABT) Finalizes Exact Sciences Acquisition to Boost Cance - GuruFocus
Abbott to close Exact Sciences acquisition on March 23 - Investing.com
Exact Sciences and Abbott receive all approvals for planned merger - Investing.com
Exact Sciences Nears Completion of Abbott Acquisition Deal - TipRanks
Abbott acquisition of Exact Sciences set to close on March 23, 2026 - Abbott MediaRoom
Cancer test maker Exact Sciences is set to join Abbott March 23 - Stock Titan
Paradiem LLC Sells 55,579 Shares of Abbott Laboratories $ABT - MarketBeat
Park National Corp OH Sells 10,527 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Acquisition Of Exact Sciences Refocuses Growth On Cancer Diagnostics - simplywall.st
Abbott Labs Q4 2025: Revenue Miss, Device Growth & Exact Sciences AcquisitionNews and Statistics - IndexBox
1 magnificent dividend stock down 22% that's a screaming buy right now - MSN
1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now - The Motley Fool
1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now - The Motley Fool
CIBC Private Wealth Group LLC Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
AIA Group Ltd Raises Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT) likely to benefit from nutrition segment recovery - MSN
Abbott Investors Ink $40M Deal Over Infant Formula Crisis - Law360
Futures Contracts for Abbott Laboratories Futures - TradingView
Selling pressure pushes Abbott Laboratories stock lower in today's trading - Traders Union
Abbott Labs Leaders, Shareholders Reach Formula Suit Settlement - Bloomberg Law News
Is Trending Stock Abbott Laboratories (ABT) a Buy Now? - Yahoo Finance
Abbott’s $21 Billion Exact Sciences Acquisition Supports a $179 Price Target - TIKR.com
Wilmington Savings Fund Society FSB Sells 25,557 Shares of Abbott Laboratories $ABT - MarketBeat
Danske Bank A S Takes $116.41 Million Position in Abbott Laboratories $ABT - MarketBeat
Coldstream Capital Management Inc. Increases Holdings in Abbott Laboratories $ABT - MarketBeat
Will New Diabetes and Cardio Data Shift Abbott Laboratories' (ABT) Chronic-Disease Innovation Narrative - simplywall.st
Abbott Laboratories Stock (ISIN: US0028241000) Hits Multi-Month Lows Amid Pullback: Buy the Dip Oppo - AD HOC NEWS
Abbott Laboratories $ABT Shares Purchased by Mariner LLC - MarketBeat
Mairs & Power Inc. Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ISIN: US0028241000) Shows Resilience Amid Healthcare Sector Headwinds, Tr - AD HOC NEWS
Mercer Global Advisors Inc. ADV Buys 79,707 Shares of Abbott Laboratories $ABT - MarketBeat
Focus Partners Wealth Has $71 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Fred Alger Management LLC Has $20.29 Million Position in Abbott Laboratories $ABT - MarketBeat
Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness and Modest Undervaluation Estimate - simplywall.st
Abbott Diabetes And Cardiology Updates Test Growth Story For Investors - Yahoo Finance
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):